Chinese drugmaker Sino Biopharmaceutical Ltd. plunged nearly 12% in Hong Kong after its third-quarter earnings missed expectations, partly due to the impact of a centralized drug procurement program on prices.
Sino Biopharm Shares Sink 12% in Hong Kong After Earnings Shock
More Stories
How to land a good work-from-home job
Pfizer’s COVID-19 vaccine has begun rolling out of its Michigan plant in a truck convoy
Iran Sets Out Ambitions to Hike Oil Production Next Year